1. Home
  2. ENVB vs SLRX Comparison

ENVB vs SLRX Comparison

Compare ENVB & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

SELL

Current Price

$10.15

Market Cap

3.0M

Sector

Health Care

ML Signal

SELL

Logo Salarius Pharmaceuticals Inc.

SLRX

Salarius Pharmaceuticals Inc.

HOLD

Current Price

$0.85

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENVB
SLRX
Founded
1994
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ENVB
SLRX
Price
$10.15
$0.85
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$120.00
N/A
AVG Volume (30 Days)
1.8M
4.8M
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.88
$0.71
52 Week High
$96.30
$108.00

Technical Indicators

Market Signals
Indicator
ENVB
SLRX
Relative Strength Index (RSI) 77.38 28.98
Support Level $5.75 $0.81
Resistance Level $6.99 $0.92
Average True Range (ATR) 0.86 0.08
MACD 0.14 0.11
Stochastic Oscillator 58.23 60.88

Price Performance

Historical Comparison
ENVB
SLRX

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Share on Social Networks: